Retrospective Chart Review of Children With Primary Immunodeficiencies (PID) Who Received Targeted Therapy of Interstitial Lymphocytic Lung Disease (ILLD) With Abatacept or Rituximab.
Latest Information Update: 07 Sep 2022
At a glance
- Drugs Abatacept (Primary) ; Rituximab (Primary)
- Indications Immunodeficiency disorders; Interstitial lung diseases
- Focus Adverse reactions
- 06 Oct 2020 New trial record